Analysis of bone architecture in the non-tumour-bearing leg confirmed that Sema3A (0.7 mg/kg/2-weekly) enhanced bone volume (% BV/TV, tibia 38% ± 6.1, femur 70% ± 13 p < 0.01) and trabecular number (% Tb.N, tibia 38% ± 5.1, femur 58% ± 9.5 p < 0.01), and connectivity (% Tb.Pf, tibia 22% ± 4.4, femur 32% ± 4.8 p < 0.01) and reduced trabecular separation (% Tb.Sp, tibia 22% ± 5.0, femur 27 ± 6.0% p < 0.05) in the control (Fig. 1 and Supplementary Figure S2). This evidence concerns the gene SEMA3A and neoplasm.